Chemours (CC) Current Deferred Revenue (2015 - 2021)

Chemours' Current Deferred Revenue history runs 7 years deep, the most recent figure standing at $3.0 million for Q4 2021.

• On a quarterly basis, Current Deferred Revenue fell 57.14% year-over-year to $3.0 million in Q4 2021; TTM through Dec 2021 was $3.0 million, a 57.14% decrease from a year earlier, with the FY2021 full-year figure at $3.0 million, down 57.14% from the prior year.
• Current Deferred Revenue rose to $3.0 million in Q4 2021 per CC's latest filing, from $2.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $23.0 million in Q1 2017 and bottomed at $2.0 million in Q3 2021.
• The 5-year median for Current Deferred Revenue is $7.0 million (2019), against an average of $7.3 million.
• Across the five-year window, Current Deferred Revenue slumped 89.47% in 2017 and jumped 60.0% in 2019, its largest moves.
• Year by year, Current Deferred Revenue stood at $8.0 million in 2017, then decreased by 25.0% to $6.0 million in 2018, then gained by 16.67% to $7.0 million in 2019, then changed by 0.0% to $7.0 million in 2020, then plunged by 57.14% to $3.0 million in 2021.
• Per Business Quant, the three latest CC Current Deferred Revenue figures stand at $3.0 million (Q4 2021), $2.0 million (Q3 2021), and $3.0 million (Q2 2021).